Ratings by Canaccord Genuity (Edward Nash)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/12/2023 | Oramed Pharma | ORMP | Downgrade | Hold (Buy) |
10.79 (1.99) |
-81.56% | Details | |
| 1/10/2023 | Amryt | AMYT | Downgrade | Hold (Buy) |
7.00 (14.66) |
109.43% | Details | |
| 1/6/2023 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2022 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2022 | Galmed Pharmaceuticals | GLMD | Downgrade | Hold (Buy) |
0.44 (0.57) |
29.55% | Details | |
| 8/2/2022 | Rezolute | RZLT | New Coverage | Buy (N/A) |
3.11 (2.39) |
-23.15% | Details | |
| 7/29/2022 | ObsEva | OBSV | Downgrade | Hold (Buy) |
0.30 (0.22) |
-26.67% | Details | |
| 6/30/2022 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2022 | Corcept Therapeutics | CORT | New Coverage | Buy (N/A) |
23.80 (22.99) |
-3.4% | Details | |
| 5/10/2022 | Intercept Pharmaceuticals | ICPT | Maintain | Hold (N/A) |
|
Details | ||
| 4/26/2022 | ObsEva | OBSV | New Coverage | Buy (N/A) |
1.58 (0.22) |
-86.08% | Details | |
| 4/18/2022 | Cardiol Therapeutics | CRDL | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2022 | Morphic Therapeutic | MORF | New Coverage | Buy (N/A) |
40.32 (32.10) |
-20.39% | Details | |
| 3/31/2022 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
13.03 (42.05) |
222.72% | Details | |
| 3/8/2022 | Intercept Pharmaceuticals | ICPT | Maintain | Hold (N/A) |
|
Details | ||
| 3/3/2022 | Akero Therapeutics | AKRO | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2021 | Cardiol Therapeutics | CRDL | New Coverage | Buy (N/A) |
2.05 (0.70) |
-65.85% | Details | |
| 11/23/2021 | Oramed Pharma | ORMP | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2021 | Akero Therapeutics | AKRO | Maintain | Buy (N/A) |
|
Details | ||
| 11/12/2021 | Verona Pharma | VRNA | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2021 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2021 | Galmed Pharmaceuticals | GLMD | Maintain | Buy (N/A) |
|
Details | ||
| 10/22/2021 | Metacrine Inc. | MTCR | Downgrade | Hold (Buy) |
3.71 (0.50) |
-86.52% | Details | |
| 9/17/2021 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Hold (N/A) |
|
Details | ||
| 7/29/2021 | Oramed Pharma | ORMP | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2021 | Theratechnologies Inc. | THTX | Downgrade | Hold (Buy) |
3.71 (0.94) |
-74.66% | Details | |
| 5/17/2021 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2021 | Travere Therapeutics | TVTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2021 | Galmed Pharmaceuticals | GLMD | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2021 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 5/3/2021 | Verona Pharma | VRNA | Maintain | Buy (N/A) |
|
Details | ||
| 4/20/2021 | Oramed Pharma | ORMP | New Coverage | Buy (N/A) |
8.46 (1.99) |
-76.48% | Details | |
| 4/19/2021 | Theratechnologies Inc. | THTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2021 | Akero Therapeutics | AKRO | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2021 | Verona Pharma | VRNA | Maintain | Buy (N/A) |
|
Details | ||
| 8/10/2020 | Verona Pharma | VRNA | New Coverage | Buy (N/A) |
7.83 (21.42) |
173.56% | Details | |
| 7/1/2020 | Akero Therapeutics | AKRO | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2020 | Akero Therapeutics | AKRO | New Coverage | Buy (N/A) |
26.09 (48.71) |
86.7% | Details | |
| 1/30/2020 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
81.75 (281.23) |
244.01% | Details |
